

The Neuro4D Conference 2025

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**MONDAY
MAY 19TH**

8:00		
Registration and Joint Breakfast, attach Posters		
8:30		
Opening of the Conference: Andreas Köpke, bioExpert		
9:00		
New modes of action for targeting neurodegenerative diseases: restoring the septin cytoskeleton <i>Chair: Gerard Griffioen, reMYND, Belgium</i>		
PANEL 09:30 – 10:30		
Protein Aggregation in Neurodegeneration	Biomolecular condensates in neurodegeneration	Markus Zweckstetter DZNE Göttingen, Germany
	Harnessing nuclear-import receptors to antagonize aberrant protein phase transitions in neurodegenerative diseases	Miriam Linsenmeier University of Pennsylvania, USA
Aβ Antibody Comparison	Comparative treatment of 5xFAD mice applying monoclonal antibodies directed against pGlu3-, isoAsp7 and Nitro-Tyr10 Abeta	Stephan Schilling Fraunhofer-Institute for Cell Therapy and Immunology, Germany
Panel Q&A of Session Speakers <i>Chair: Gerard Griffioen, reMYND, Belgium</i>		
10:30 – 11:30		
Coffee Break, Exhibition & Poster Viewing		
PANEL 11:30 – 12:30		
Tau Antibodies as Novel Therapeutic Option	Clearance of intracellular tau protein pathology through novel immunotherapy approaches	Rakez Kaye UMTB, USA
In vivo Disease Models	Preclinical strategies for assessment of therapeutics targeting early stages of proteinopathies	Joseph Arauja Transpharmation, Canada
	Development and characterization of a dual (amyloid and tau) pathology mouse model for Alzheimer's disease	Julian Sefrin Abbvie, Germany
Panel Q&A of Session Speakers <i>Chair: Gerard Griffioen, reMYND, Belgium</i>		
12:30		
Lunch		

The Neuro4D Conference 2025

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**MONDAY
MAY 19TH**

13:30

Protein degradation mechanisms as novel therapeutic approaches for neurodegenerative diseases
Chair: Christiane Volbracht, H. Lundbeck, Denmark

PANEL 14:00 – 15:00

New Treatment Modality	Induced proximity probes for therapeutic concepts in neurodegenerative diseases	William Farnaby University of Dundee, UK
Proteomics Services	Characterizing target degrader compounds on the protein level in cell culture and tissue samples	Hannes Hahne OmicScouts, Germany
New Treatment Modality	BioPROTAC degradation of misfolded SOD1 as a potential therapeutic for amyotrophic lateral sclerosis (ALS)	Christen Chisholm University of Wollongong, Australia

Panel Q&A of Session Speakers
Chair: Christiane Volbracht, H. Lundbeck, Denmark

15:00 – 16:00

Coffee Break, Exhibition & Poster Session
All Presenters will be at their posters for discussion.
Time for One on One Meetings

PANEL 16:00 – 17:00

New Treatment Modality	Reliable intrabodies for neurodegenerative disease	Gareth Wright University of Essex, UK
In vivo Disease Models	The combination of genetic and induced risk factors in animal models of aging	Lone Bruhn Madsen Scantox, Sweden
New Treatment Modality	PRI-101, an optimized oligomer-disassembling compound as potential drug candidate for synucleinopathies	Antje Willuweit Priavoid, Germany

Panel Q&A of Session Speakers
Chair: Christiane Volbracht, H. Lundbeck, Denmark

17:00

Reception in the Foyer

18:30 – 22:00

Dinner

We will have a seated dinner, accompanied by fitting local wines!
Depending on the weather, we will be on the hotel terrace, or in an adjacent room.

END OF THE FIRST DAY

The Neuro4D Conference 2025

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**TUESDAY
MAY 20TH**

8:00		
Joint Breakfast, Exhibition & Poster Viewing		
8:30		
<p>Therapeutic vaccines and antibodies for AD, PD and ALS <i>Chair: Neil Cashman, ProMIS Neurosciences, Canada</i></p>		
PANEL 9:00 – 10:00		
Finding new AD Targets	Harnessing viruses for drug discovery and target identification in neurodegenerative diseases	Carsten Korth Heinrich Heine University, Germany
Diagnosis of Prion Disease	Fluid biomarker-led subject stratification and enrichment for primary prevention strategies in individuals at risk of prion disease	Tzehow Mok Institute of Prion Diseases and MRC Prion Unit, UK
New Treatment Modality and Route of Administration	Nose-to-brain small RNA delivery to treat Parkinson's disease	Franziska Richter Assencio University of Hannover, Germany
<p>Panel Q&A of Session Speakers <i>Chair: Neil Cashman, ProMIS Neurosciences, Canada</i></p>		
10:00 – 11:00		
<p>Coffee Break, Exhibition & Poster Session All Presenters will be at their posters for discussion. Time for One on One Meetings</p>		
PANEL 11:00 – 12:00		
PD Diagnostics	Diagnosis of Parkinson's disease from peripheral tissues	Walter J. Schulz-Schaeffer University of the Saarland, Germany
AD Diagnostic	Alzheimer's diagnosis based on fluid biomarkers only: Future or fiction?	Oliver Peters Charité, Germany
Repurposed Therapeutic	Levodopa use in Alzheimer's disease and spinocerebellar ataxia type 3: molecular, preclinical and clinical evidence	Pedro Martins Instituto de Biologia Molecular e Celular – IBMC, Portugal
<p>Panel Q&A of Session Speakers <i>Chair: Neil Cashman, ProMIS Neurosciences, Canada</i></p>		
12:00		
Lunch		

The Neuro4D Conference 2025

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**TUESDAY
MAY 20TH**

13:00

Implementation of new Amyloid antibody treatments in Germany – guidance and challenges
Chair: Lutz Froelich, University of Heidelberg, Germany

PANEL 13:30 – 14:30

AD Clinical Development	PRI-002 for the treatment of Alzheimer's disease	Dieter Wilbold Priavoid, Germany
	Eisai's pipeline in Alzheimer's disease	Daniela Rossi Eisai, UK
	Is there a continued benefit for Long-Term Treatment from the OLE data of Eisai's Clarity-AD Study?	Oliver Peters Charité, Germany

Panel Q&A of Session Speakers

Chair: Lutz Froelich, University of Heidelberg, Germany

14:30

Coffee Break & Final Poster Session

15:00

Pannel Discussion: Current therapeutic options and future implications

- When to best start therapy in Alzheimers disease with the newly registered antibodies? How much patient benefit can be achieved?
- What achievements do we need from the next successful AD therapeutic to make a meaningful difference over current standard of treatment?
- Which role do symptomatic therapies play to keep patients autonomous?

Pannel Participants:

Lutz Froehlich, Oliver Peters, Gerard Griffioen, Neil Cashman

Moderator:

Andreas Köpke

16:15

Summary and Wrap-Up of the Conference

16:30

END OF THE CONFERENCE AND DEPARTURE